Conclusion - Recommandations
Les maladies veineuses thrombo-emboliques sont une
réalité courante dans nos hôpitaux. Leur prise en charge
souffre de nombreuses insuffisances liées au manque d'équipement
et à la faible mobilisation des praticiens face à ce
fléau. Il apparaît impératif que des actions
menées :
· Par les équipes de recherche pour renforcer les
données épidémiologiques sur ces affections dans notre
environnement.
· Par les formateurs pour mettre plus d'emphase sur la
sensibilisation des praticiens sur les méthodes de prise en charge.
· Par les institutions hospitalières et
l'état pour construire et implémenter une politique
cohérente autour des MVTE (création « d'hôpitaux
du jour », réduction des coûts, ...).
Références:
1. Heit J.A. The epidemiology of venous thromboembolism in the
community: implications for prevention and management J Thromb
Thrombolysis 2006; 21:23-29
2. White R.H. The epidemiology of venous thromboembolism
Circulation 2003; 107:I4-I8
3. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon
WN, Melton III LJ. Trends in the incidence of deep ven thrombosis and pulmonary
embolism. Arch Intern Med 1998; 158:585-93.
4. Fowkes F.J., Price J.F., Fowkes F.G. Incidence of diagnosed
deep vein thrombosis in the general population: systematic review Eur J
Vasc Endovasc Surg 2003; 25:1-5
5. Boukinda F, Planchon B, Okondza J. La
thrombophlébite profonde des members inférieurs: une
curiosité clinique en Afrique noire. Notre expérience à
Brazzaville. Med Af Noire 1996 ; 2 :63-65.
6. Bertrand E, Coulibaly Ao, Ticolat R. Statistiques 1988,
1989 e 1990 de l'institut de cardiologie d'Abidjan (ICA). Cardiol Trop
1991 ; 17 :151-154.
7. S. Kingue, D. Tagny-Zukam, F. Binam, C. Nouedoui, A.
Teyang, W.F.T. Muna. La maladie thrombo-embolique veineuse au Cameroun
(à propos de 18 cas). Med Trop 2002 ; 62 :47-50.
8. Cheuk BL, Cheung GC, Cheng SW. Epidemiology of venous
thromboembolism in Chinese population. Br J Surg 2004
Apr;91(4):424-8.
9. A.T. Cohen, V.F. Tapson, J.F. Bergman, S.Z. Goldhaber, A.K.
Kakkar, F.A. Anderson. Late breaking clinical trial : A Large-Scale,
Global Observational Study of venous Thromboembolism Risk and
Prophylaxis : the Acute Hospital Care Setting : The Endorse Study.
O-S-002.
10. Abdool-Carim T, Adler H, Becker P et al. The cost and
benefit of prophylaxis against DVT in elective hip replacement: DVT/PE
prophylaxis consensus forum. South African Med J 1997
87(5):594-600.
11. AF Ouro-bang'na Maman, N Agbetra, A Abalo, P agbohou, K
Tomta and M Chobli. Pratique de la prophylaxie thromboembolique veineuse:
enquête auprès des chirurgiens et anesthésistes au Togo.
Annales françaises d'anesthésie et de réanimation
2006 ; 25 : 1107-1110.
12. Oger E. Incidence of venous thromboembolism: a
community-based study in Western France. Epi-Getbo Study Group d'étude
de la thrombose de Bretagne Occidentale Thromb Haemost 2000 ;
83657-660I
13. Anderson FAJr, Wheeler HB, Goldberg RJ, Hosmer DW,
Patwar-han NA, Jovanovic B et al. A population-based perspective of the
hospital incidence and case-fatality rates Worcester DVT Study. Arch Intern
Med 1991; 151:933-938.
14.
www.gita-thrombose.org
15. Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW,
Anderson FAJr et al. Prevention of venous thromboembolism. Chest 2001;
119 suppl1: 132S-175S.
16. Nordstrom M, Lindblad B, Anderson H, Bergqvist D,
Kjel-Istrom T. Deep venous thrombosis and occult malignancy: an epidemiological
study Br Med J 1994; 308891-894.
17. Ginsberg JS, Greer I, Hirsh J. Use of antithrombotic
agents during pregnancy. Chest 2001; 119 suppl1: 122S-131S.
18. Anderson FAJr, Wheeler HB. Venous thromboembolism. Risk
factors and prophylaxis. Clin Chest Med 1995; 16: 235-251.
19. De Moerlose P, Boneu B. Traitement anticoagulant et
éducation du patient: une nécessité. Sang Thromb Vaiss
1999 ; 9 : 647-652.
20. Hankey GJ, Eikelboom JW. Homocysteine and vascular
disease. Lancet 1999; 354: 407-413.
21. Hansson PO, Sorbo J, Eriksson H. Recurrent
thromboembolism after deep vein thrombosis. Arch Intern Med 2000;
160:769-774.
22. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh
S. Risk of venous thromboembolism in user of hormone replacement therapy.
Lancet 1996; 348: 977-980.
23. Cronan JJ. Venous duplex US of the lower extremities:
effect of duplicated femoral veins. Radiology 1998; 206: 308-309.
24. Kestven PJ, Robinson BJ. Clinical risk factors of venous
thrombosis associated with travel. Aviat Space Environ Med 2001; 72:
125-128.
25. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven
RJ, de Ronde H et al. Mutation in blood coagulation factor V associated with
resistance to activated protein C. Nature 1994; 369: 64-67.
26. Kamphuisen PW, Eikenboom JC, Bertina RM. Elevated factor
VIII and the risk of thrombosis. Arterioscler Thromb Vasc Biol 2001;
21: 731-738.
27. Wells PS, Hirsh J, Anderson DR, Lensing AW, Foster G,
Kearon C, et al. A simple clinical model model for the diagnostic of deep vein
thrombosis combined with impedance pletysmography: potential for an improvement
in the diagnostic process. J Intern Med 1998; 243:15-23.
28. Bernardi E, Prandoni P, Lensing AW, Agnelli G, Guazzaloca
G, Scannapieco G et al. A D-dimer testing as an adjunct to ultrasonography in
patients with clinically suspected deep vein thrombosis: prospective cohort
syudy. Br Med J 1998; 317: 1037-1040.
29. Dauzat M, Laroche JP, Deklunder G, et al. Diagnosis of
acute lower limb deep venous thrombosis with ultrasound: Trends and
controuversies. J clin Ultrasound 1997; 25: 343-58.
30. Perrier A, Desmarais S, Miron MJ, de Moerloose P, Lepage
R, Slosman D et al. Non -invasive diagnosis of venous thromboembolism in
out-patients Lancet 1999 ; 353190-195.
31. Boccalon H, Elias A, Chale J-J, Cadene A, Gabriel S,
Clinical outcome and cost of hospital versus home treatment of proximal deep
venous with a low-molecular-weight heparin: The Vascular Midi Pyrenees tudy.
Arch Intern Med 2000; 160: 1769-73.
32. Hommes DW, Bura A, Mazzolai L, Buller HR, ten Cate JW.
Subcutaneous heparin compared with continuous intravein thrombosis. A
metaanalysis. Ann Intern Med 1992; 116: 279-284.
33. Ageno W, Johnson J, Nowacki B, Turpie AG. A computer
generated induction system for hospitalized patients starting an oral
anticoagulant therapy. Thromb Haemost 2000; 83: 849-852.
34. Cazaux V, Gauthier B, Elias A, Lefevre D, Tredez J,
Nguyen F et al. Predicting daily maintenance of fluindione, an oral
anticoagulant drug. Thromb Haemost 1996; 75: 731-733.
35. Leger P. Les cas cliniques d'anticoagulants. Sang
Thromb Vaiss 2003 ; (sous presse).
36. Chiquette E, Amato MG, Bussy HI. Comparison of an
anticoagulation clinic with usual medical care: anticoagulation control,
patient outcomes, and health care costs. Arch Intern Med 1998; 158:
1641-1647.
37. Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Ioro
A, Bazzan M et al. Three-months compared with one-year of oral anticoagulant
treatment after a first idiopathic deep vein thrombosis: the Warfarin Optimal
Duration Italian Trial (WODIT) study. N Engl J 2001; 345: 165-169.
38. Fennerty AG, Dolben J, Thomas P, Backhouse G, Bentley DP,
Campbell IA et al. A comparison of 3 and 6 weeks anticoagulation in the
treatment of venous thrombolism. Clin Lab Haematol 1987; 9: 17-21.
39. Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Elby
CS, Dietcher SR et al. Long-term, low-intensity warfarin therapy for the
prevention of recurrent venous thromboembolism N Engl Med 2003;
3481425-1434.
40. Brandjes DBM, Buller HR, Heilboer H, Huisman MV, de Rijk
M, Jagt H, et al. Randomised trial of effect of compression stockings in
patients wisth symptomatic proximal-vein thrombosis. Lancet 1997;
349:759-62.
41. Prandoni P, Lensing AWA, Cogo A, Cupini S, Villata S,
Carta M, et al. The long term clinical course of acute deep venous thrombosis.
Ann Intern Med. 1996; 1251: 1-7.
42. Elias A, Fiessinger JN. Maladie thromboembolique
veineuse. Collection de Médecine Vasculaire. Paris : Masson,
1995.
43. Bates SM, Ginsberg JS. How we manage venous
thromboembolism during pregnancy. Blood 2002; 100: 3470-3478.
44. J.L. Bosson, M.A. Sevestre, I. Quéré, J.P.
Laroche and Société Française de Médecine
Vasculaire. La maladie thromboembolique est-elle une entité
homogène ? A propos de l'étude OPTIMEV. La revue de la
Médecine Interne 2006 ; 27 suppl 3 : S301.
45. Ricky Autar et al. The management of deep vein
thrombosis: the Autar DVT risk assessment scale re-visited. Journal of
Orthop Nurs 2003; 7: 114-124.
46. Adoh M, Konin C, Aevouelie Kouassi F, Anzouan-Kacou JB,
DIBI F et al. Influence du climat tropical sur l'incidence des TVP des members
inférieurs. Card Trop 2004 ; 118(30) :28-30.
47. Anderson DR, Wells PS. Improvements in the diagnosis
approach for patients with suspected DVT or PE. Thromb Haemos 1999;
82: 878-86.
49. S Prasannan, LN Chin, YA Gul, . VTE diseases prophylaxis
among general surgeons in Malaysia. Asian Journal of Surgery 2005;
28(2): 125-30.
| 
